Purinergic P2Y2 receptors mediate rapid Ca2+ mobilization, membrane hyperpolarization and nitric oxide production in human vascular endothelial cells

Cell Calcium

Volumn 49, Issue 4, 2011, Pages 240-248

  Raqeeb, Abdul ^a   Sheng, Jianzhong ^a   Ao, Ni ^a   Braun, Andrew P ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Calcium; Hyperpolarization; Knockdown; Nitric oxide; Purinergic receptors

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALPHA,BETA METHYLENEADENOSINE TRIPHOSPHATE; CALCIUM ION; HISTAMINE; ISOPROTEIN; MESSENGER RNA; NITRIC OXIDE; PURINERGIC P2X RECEPTOR; PURINERGIC P2Y2 RECEPTOR; PYRIDOXAL PHOSPHATE 6 AZOPHENYL 2',4' DISULFONIC ACID; RECEPTOR SUBTYPE; SMALL INTERFERING RNA; TRINITROPHENYL; URIDINE TRIPHOSPHATE;

ARTICLE; CALCIUM MOBILIZATION; CELL ISOLATION; ENDOTHELIUM CELL; EVOKED RESPONSE; HUMAN; HUMAN CELL; HUMAN TISSUE; MEMBRANE HYPERPOLARIZATION; MEMBRANE POLARIZATION AND DEPOLARIZATION; MEMBRANE POTENTIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE RELAXATION; UMBILICAL VEIN; VASCULAR ENDOTHELIUM; VASODILATATION;

EID: 79955122679     PISSN: 01434160     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ceca.2011.02.008     Document Type: Article

References (23)

1. von Kügelgen I. Pharmacological profiles of cloned mammalian P2Y-receptor subtypes. Pharmacol. Therap. 2006, 110:415-432.
2. North R.A., Surprenant A. Pharmacology of cloned P2X receptors. Annu. Rev. Pharmacol. Toxicol. 2000, 40:563-580.
3. Busse R., Fleming I., Hecker M. Signal transduction in endothelium-dependent vasodilatation. Eur. Heart J. 1993, 14(Suppl. 1):2-9.
4. Busse R., Edwards G., Félétou M., Fleming I., Vanhoutte P.M., Weston A.H. EDHF: bringing the concepts together. TIPS 2002, 23:374-380.
5. Sheng J.-Z., Braun A.P. Small- and intermediate-conductance Ca2+-activated K+ channels directly control agonist-evoked nitric oxide synthesis in human vascular endothelial cells. Am. J. Physiol. Cell Physiol. 2007, 293:C458-C467.
6. Sheng J.-Z., Arshad F., Braun J.E., Braun A.P. Estrogen- and the Ca2+-mobilizing agonist ATP evoke acute nitric oxide synthesis via distinct pathways in an individual human vascular endothelial cell. Am. J. Physiol. Cell Physiol. 2008, 294:C1531-C1541.
7. Sheng J.-Z., Ella S., Davis M.J., Hill M.A., Braun A.P. Openers of SKCa and IKCa channels enhance agonist-evoked endothelial nitric oxide synthesis and arteriolar dilation. FASEB J. 2009, 23:1138-1145.
8. Sheng J.-Z., Wang D., Braun A.P. DAF-FM (4-amino-5-methylamino-2',7'-difluorofluorescein) diacetate detects impairment of agonist-stimulated nitric oxide synthesis by elevated glucose in human vascular endothelial cells: reversal by vitamin C and l-sepiapterin. J. Pharmacol. Exp. Ther. 2005, 315:931-940.
9. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685.
10. Koolpe M., Pearson D., Benton H.P. Expression of both P1 and P2 purine receptor genes by human articular chondrocytes and profile of ligand-mediated prostaglandin E2 release. Arthritis Rheum. 1999, 42:258-267.
11. Ralevic V., Burnstock G. Receptors for purines and pyrimidines. Pharmacol. Rev. 1998, 50:413-492.
12. Lambrecht G. Agonists and antagonists acting at P2X receptors: selectivity profiles and functional implications. N.-S. Arch. Pharmacol. 2000, 362:340-350.
13. Kennedy C., Qi A.D., Herold C.L., Harden T.K., Nicholas R.A. ATP, an agonist at the rat P2Y4 receptor, is an antagonist at the human P2Y4 receptor. Mol. Pharmacol. 2000, 57:926-931.
14. Parr C.E., Sullivan D.M., Paradiso A.M., Lazarowski E.R., Burch L.H., et al. Cloning and expression of a human P2U nucleotide receptor, a target for cystic fibrosis pharmacotherapy. Proc. Natl. Acad. Sci. U.S.A. 1994, 91:3275-3279.
15. Gökecke S., Decking U.K., Gödecke A., Schrader J. Cloning of the rat P2U receptor and its potential role in coronary vasodilation. Am. J. Physiol. Cell Physiol. 1996, 270:C570-C577.
16. Winter P., Dora K.A. Spreading dilatation to luminal perfusion of ATP and UTP in rat isolated small mesenteric arteries. J. Physiol. (Lond.) 2007, 582:335-347.
17. Lazarowski E.R., Watt W.C., Stutts M.J., Boucher R.C., Harden T.K. Pharmacological selectivity of the cloned human P2U-purinoceptor: potent activation by diadenosine tetraphosphate. Br. J. Pharmacol. 1995, 116:1619-1627.
18. Wang L., Karlsson L., Moses S., Hultgardh-Nilsson A., Andersson M., et al. P2 receptor expression profiles in human vascular smooth muscle and endothelial cells. J. Cardiovasc. Pharmacol. 2002, 40:841-853.
19. Goncalves da Silva C., Specht A., Wegiel B., Ferran C., Kaczmarek E. Mechanism of purinergic activation of endothelial nitric oxide synthase in endothelial cells. Circulation 2009, 119:871-879.
20. Yamamoto K., Korenaga R., Kamiya A., Qi Z., Sokabe M., Ando J. P2X4 receptors mediate ATP-induced calcium influx in human vascular endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 2000, 279:H285-H292.
21. Schwiebert L.M., Rice W.C., Kudlow B.A., Taylor A.L., Schwiebert E.M. Extracellular ATP signaling and P2X nucleotide receptors in monolayers of primary human vascular endothelial cells. Am. J. Physiol. 2002, 282:C289-C301.
22. Garcia-Guzman M., Soto F., Gomez-Hernandez J.M., Lund P.-E., Stühmer W. Characterization of recombinant human P2X4 receptor reveals pharmacological differences to the rat homologue. Mol. Pharmacol. 1997, 51:109-118.
23. Jones C.A., Chessell I.P., Simon J., Barnard E.A., Miller K.J., et al. Functional characterization of the P2X4 receptor orthologues. Br. J. Pharmacol. 2000, 129:388-394.